Development of An Oral Treatment with the PPAR-γ-Acting Cannabinoid VCE-003.2 Against the Inflammation-Driven Neuronal Deterioration in Experimental Parkinson’s Disease

In a recent study, we described the neuroprotective properties of VCE-003.2—an aminoquinone derivative of the non-psychotropic phytocannabinoid cannabigerol (CBG)—administered intraperitoneally (i.p.) in an inflammatory model of Parkinson’s disease (PD). We also demonst...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Sonia Burgaz, Concepción García, Maria Gómez-Cañas, Eduardo Muñoz, Javier Fernández-Ruiz
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI AG 2019-07-01
Colecção:Molecules
Assuntos:
cannabinoids
VCE-003.2
oral formulation
PPAR-γ
γ receptors
inflammation
Parkinson’s disease
Acesso em linha:https://www.mdpi.com/1420-3049/24/15/2702
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados